{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:47:13Z","timestamp":1761101233078},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T00:00:00Z","timestamp":1385337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/bmt.2013.180","type":"journal-article","created":{"date-parts":[[2013,11,25]],"date-time":"2013-11-25T11:41:06Z","timestamp":1385379666000},"page":"355-360","source":"Crossref","is-referenced-by-count":29,"title":["Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT"],"prefix":"10.1038","volume":"49","author":[{"given":"M","family":"Murata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Nakaseko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Morishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Nagamura-Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,11,25]]},"reference":[{"key":"BFbmt2013180_CR1","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","volume":"342","author":"A Tefferi","year":"2000","unstructured":"Tefferi A . Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255\u20131265.","journal-title":"N Engl J Med"},{"key":"BFbmt2013180_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1053\/j.seminhematol.2005.05.018","volume":"42","author":"G Barosi","year":"2005","unstructured":"Barosi G, Hoffman R . Idiopathic myelofibrosis. Semin Hematol 2005; 42: 248\u2013258.","journal-title":"Semin Hematol"},{"key":"BFbmt2013180_CR3","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895\u20132901.","journal-title":"Blood"},{"key":"BFbmt2013180_CR4","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703\u20131708.","journal-title":"Blood"},{"key":"BFbmt2013180_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392\u2013397.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013180_CR6","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1038\/bcj.2012.3","volume":"2","author":"K Ballen","year":"2012","unstructured":"Ballen K . How to manage the transplant question in myelofibrosis. Blood Cancer J 2012; 2: e59.","journal-title":"Blood Cancer J"},{"key":"BFbmt2013180_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ajh.23384","volume":"88","author":"A Tefferi","year":"2013","unstructured":"Tefferi A . Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 141\u2013150.","journal-title":"Am J Hematol"},{"key":"BFbmt2013180_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09108.x","volume":"157","author":"C Harrison","year":"2012","unstructured":"Harrison C, Verstovsek S, McMullin MF, Mesa R . Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol 2012; 157: 426\u2013437.","journal-title":"Br J Haematol"},{"key":"BFbmt2013180_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1365-2141.2012.09107.x","volume":"157","author":"DP McLornan","year":"2012","unstructured":"McLornan DP, Mead AJ, Jackson G, Harrison CN . Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 2012; 157: 413\u2013425.","journal-title":"Br J Haematol"},{"key":"BFbmt2013180_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 2010; 16: 358\u2013367.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013180_CR11","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kr\u00f6ger","year":"2009","unstructured":"Kr\u00f6ger N, Holler E, Kobbe G, Bornh\u00e4user M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264\u20135270.","journal-title":"Blood"},{"key":"BFbmt2013180_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MOH.0b013e3283257ab2","volume":"16","author":"DY Zang","year":"2009","unstructured":"Zang DY, Deeg HJ . Allogeneic hematopoietic cell transplantation for patients with myelofibrosis. Curr Opin Hematol 2009; 16: 140\u2013146.","journal-title":"Curr Opin Hematol"},{"key":"BFbmt2013180_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011; 29: 761\u2013770.","journal-title":"J Clin Oncol"},{"key":"BFbmt2013180_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/BF03006932","volume":"86","author":"Y Atsuta","year":"2007","unstructured":"Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol 2007; 86: 269\u2013274.","journal-title":"Int J Hematol"},{"key":"BFbmt2013180_CR15","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825\u2013828.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013180_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204\u2013217.","journal-title":"Am J Med"},{"key":"BFbmt2013180_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367\u2013369.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013180_CR18","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFbmt2013180_CR19","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457\u2013481.","journal-title":"J Am Stat Assoc"},{"key":"BFbmt2013180_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life tables. J Royal Stat Soc [B] 1972; 34: 187\u2013220.","journal-title":"J Royal Stat Soc [B]"},{"key":"BFbmt2013180_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bbmt.2006.11.004","volume":"13","author":"DM Kerbauy","year":"2007","unstructured":"Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355\u2013365.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt2013180_CR22","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3324\/haematol.12828","volume":"93","author":"F Patriarca","year":"2008","unstructured":"Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 2008; 93: 1514\u20131522.","journal-title":"Haematologica"},{"key":"BFbmt2013180_CR23","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","volume":"116","author":"H Alchalby","year":"2010","unstructured":"Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572\u20133581.","journal-title":"Blood"},{"key":"BFbmt2013180_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2141.2010.08417.x","volume":"152","author":"M Robin","year":"2011","unstructured":"Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). Br J Haematol 2011; 152: 331\u2013339.","journal-title":"Br J Haematol"},{"key":"BFbmt2013180_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2141.2011.09009.x","volume":"157","author":"H Alchalby","year":"2012","unstructured":"Alchalby H, Yunus DR, Zabelina T, Kobbe G, Holler E, Bornh\u00e4user M et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012; 157: 75\u201385.","journal-title":"Br J Haematol"},{"key":"BFbmt2013180_CR26","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood-2011-08-372904","volume":"119","author":"BL Scott","year":"2012","unstructured":"Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119: 2657\u20132664.","journal-title":"Blood"},{"key":"BFbmt2013180_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/bmt.2009.188","volume":"45","author":"A Bacigalupo","year":"2010","unstructured":"Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45: 458\u2013463.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013180_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/blood-2009-11-252601","volume":"116","author":"S Takagi","year":"2010","unstructured":"Takagi S, Ota Y, Uchida N, Takahashi K, Ishiwata K, Tsuji M et al. Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. Blood 2010; 116: 649\u2013652.","journal-title":"Blood"},{"key":"BFbmt2013180_CR29","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/bmt.2010.14","volume":"45","author":"WA Stewart","year":"2010","unstructured":"Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010; 45: 1587\u20131593.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013180_CR30","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2004-11-4299","volume":"105","author":"D Rondelli","year":"2005","unstructured":"Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115\u20134119.","journal-title":"Blood"},{"key":"BFbmt2013180_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/bmt.2010.276","volume":"46","author":"S Lissandre","year":"2011","unstructured":"Lissandre S, Bay JO, Cahn JY, Porcher R, Cacheux V, Cabrespine A et al. Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis. Bone Marrow Transplant 2011; 46: 557\u2013561.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt2013180_CR32","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","volume":"102","author":"HJ Deeg","year":"2003","unstructured":"Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102: 3912\u20133918.","journal-title":"Blood"},{"key":"BFbmt2013180_CR33","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1182\/blood.V99.6.2255","volume":"99","author":"SM Devine","year":"2002","unstructured":"Devine SM, Hoffman R, Verma A, Shah R, Bradlow BA, Stock W et al. Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood 2002; 99: 2255\u20132258.","journal-title":"Blood"},{"key":"BFbmt2013180_CR34","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1046\/j.1365-2141.2002.03884.x","volume":"119","author":"J Hessling","year":"2002","unstructured":"Hessling J, Kr\u00f6ger N, Werner M, Zabelina T, Hansen A, Kordes U et al. Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 119: 769\u2013772.","journal-title":"Br J Haematol"},{"key":"BFbmt2013180_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/j.1365-2141.2005.05373.x","volume":"128","author":"N Kr\u00f6ger","year":"2005","unstructured":"Kr\u00f6ger N, Zabelina T, Schieder H, Panse J, Ayuk F, Stute N et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005; 128: 690\u2013697.","journal-title":"Br J Haematol"},{"key":"BFbmt2013180_CR36","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2141.2006.06302.x","volume":"135","author":"M Merup","year":"2006","unstructured":"Merup M, Lazarevic V, Nahi H, Andreasson B, Malm C, Nilsson L et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 2006; 135: 367\u2013373.","journal-title":"Br J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bmt2013180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bmt2013180","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bmt2013180.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T09:46:29Z","timestamp":1716198389000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt2013180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,25]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFbmt2013180"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2013.180","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,25]]}}}